Navigation Links
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Date:12/19/2011

>

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the pr
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
5. 23andMe Announces Breast Cancer Initiative
6. Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
9. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Eckert & Ziegler Vitalea Science ... services to the pharmaceutical and biotech industry, has announced ... in the position of Director of Science & Technology. ... valuable experience in drug metabolism and bioanalysis to EZVS ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... For the second month in a row,the capital markets succumbed ... day of the month the Dow dropped over 300 points ... time. Amid these,fears, biotech was dragged down with the Burrill ... and the Dow, which closed down,3%., "The biotech sector ...
... BEACH, Va., March 3 LifeNet Health,a leading ... This product has been engineered for anterior,cervical fusion ... The new VG1(R) Cervical Bio-implant was co-developed ... represented in the U.S. by DePuy,Spine., "VG1(R) ...
... Calif., March 3 ROBODOC, a Curexo,Technology Company, ... into a,major patent Cross licensing agreement. The terms ... In addition to its current surgical robotics ... 40,000 patents in IBM,S Global Portfolio,and particularly, IBM,s ...
Cached Biology Technology:Biotech Drops Amid Tough Markets in February 2Biotech Drops Amid Tough Markets in February 3LifeNet Health(R) Unveils New Biomedical Spine Implant 2ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Institutes of Health have identified a gene associated with ... attacks, irresistible bouts of sleep that can strike at ... has a known role in the immune system, which ... turns against the body,s own tissues, plays an important ...
... May 3, 2009 Ben W. Strowbridge, Ph.D, associate professor ... student in the neurosciences program at Case Western Reserve ... a form of synaptic memory in the olfactory bulb, ... of smell. Their study, entitled "Long-term plasticity of ...
... 2009 Two scientists whose work has led to new ... have been chosen to receive the 2009 March of Dimes ... and Louis M. Kunkel, Ph.D., will share the 2009 March ... and proteins that cause muscular dystrophy, a disorder in which ...
Cached Biology News:Genetic study confirms the immune system's role in narcolepsy 2Genetic study confirms the immune system's role in narcolepsy 3Neuroscientists discover long-term potentiation in the olfactory bulb 2Neuroscientists discover long-term potentiation in the olfactory bulb 3March of Dimes awards $250,000 prize to scientists unraveling the causes of muscular dystrophy 2
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
...
Biology Products: